Navigation Links
Press conference schedule announced for TCT 2009
Date:8/27/2009

WHAT:

Data from late-breaking clinical trials of new interventional techniques and devices will be released at TCT 2009 - Transcatheter Cardiovascular Therapeutics the global annual scientific symposium of the Cardiovascular Research Foundation. Researchers will present a variety of new data that promises to advance the field of interventional cardiology.

The TCT 2009 final program is now available at: http://www.tctconference.com/pdf/tct2009-final-program.pdf. The program is also now searchable online by presentations and speakers at: http://www.tctconference.com/program/program-search.html.

WHEN: The TCT Scientific Symposium will be held September 21-25, 2009.

Late-breaking clinical trials will be highlighted during press conferences scheduled for Wednesday, September 23, Thursday, September 24, and Friday, September 25.

Wednesday, September 23, 2009
9:30am - 10:30am

  • SPIRIT IV: A Prospective Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents
  • FAME: Two-Year Follow-up from a Prospective Randomized Trial of FFR-Guided vs. Angiography-Guided PCI in Patients with Multivessel Coronary Artery Disease
  • ISAR-DESIRE 2: A Prospective Randomized Trial of Paclitaxel-Eluting vs. Sirolimus-Eluting Stents for Treatment of Sirolimus-Eluting Stent Restenosis
  • SIRTAX-LATE: Five-Year Clinical and Angiographic Follow-up from a Prospective Randomized Trial of Paclitaxel-Eluting and Sirolimus-Eluting Stents
  • LEADERS: Two-Year Follow-up from a Prospective Randomized Trial of Biolimus A9-Eluting Stents with a Bioabsorbable Polymer vs. Sirolimus-Eluting Stents with a Durable Polymer
  • COMPARE: A Prospective Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents

Thursday, September 24, 2009
9:00am - 10:00am

  • TRITON-TIMI 38 ECONOMIC SUBSTUDY: Cost-Effectiveness of Prasugrel vs. Clopidogrel from a Prospective Randomized Trial of Patients with ACS Undergoing PCI
  • CURRENT-PCI OASIS 7: A Prospective, Randomized, Placebo-Controlled Trial of High- vs. Standard-Dose Clopidogrel and High- vs. Low-Dose Aspirin in Patients Undergoing PCI for ACS
  • PROSPECT: A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively Identify Vulnerable Plaque
  • COGENT: A Prospective, Randomized, Placebo-Controlled Trial of Omeprazole in Patients Receiving Aspirin and Clopidogrel
  • CHARISMA GENOMICS SUBSTUDY: Evaluation of the CYP2C19 Polymorphism in a Prospective, Randomized, Placebo-Controlled Trial of Chronic Clopidogrel Use for Primary and Secondary Prevention
  • PLATO INVASIVE: A Prospective, Randomized, Placebo-Controlled Trial of Ticagrelor vs. Clopidogrel in Patients with ACS Managed with an Invasive Strategy

Friday, September 25, 2009
9:30am - 10:30am

  • SYMPLICITY 1: One-Year Results Following Sympathetic Renal Denervation in Refractory Hypertension
  • DEBATER: A Prospective Randomized Trial of Drug-Eluting vs. Bare-Metal Stents With or Without Abciximab in STEMI
  • BCIS-1: A Prospective Randomized Trial of Intra-Aortic Balloon Pump Counterpulsation in High-Risk Patients Undergoing PCI
  • FAUST: A Prospective Randomized Trial of Ultrasound-Guided vs. Standard Femoral Arterial Access
  • NORDIC-BALTIC BIFURCATION STUDY III: A Prospective Randomized Trial of Side Branch Dilatation Strategies in Patients with Coronary Bifurcation Lesions Undergoing Treatment with a Single Stent
  • HORIZONS-AMI: Two-Year Follow-up from a Prospective Randomized Trial of Heparin Plus Glycoprotein IIb/IIIa Inhibitors vs. Bivalirudin and Paclitaxel-Eluting vs. Bare-Metal Stents in STEMI

WHERE:
The Moscone Center
San Francisco, CA


'/>"/>

Contact: Judy Romero
jromero@crf.org
212-851-9311
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
2. Children of depressed moms do better when dad is involved, SLU researcher finds
3. Clinical depression linked to abnormal emotional brain circuits
4. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
5. Specific antagonism lowers blood pressure
6. Are too many people diagnosed as depressed?
7. Depression Taking Toll on Returning U.S. Vets
8. Doctors Often Miss High Blood Pressure in Kids
9. Pill box organizers increase HIV patients adherence and improve viral suppression
10. Damp, Moldy Homes May Cause Depression
11. Treating depression may improve recovery of heart rate variability following coronary syndromes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... ... April 30, 2016 , ... ... President and CEO of EMED, today signed a multifaceted agreement which will allow ... the Northern Caribbean University Department of Natural and Applied Sciences, Allied Health and ...
(Date:4/29/2016)... ... 30, 2016 , ... Mercy College is expanding its Graduate Business Programs to ... expanding due to high demand: Master of Business Administration (MBA), Master of Organizational Leadership ... , School of Business Graduate Program Chair Dr. Ray Manganelli said: “We believe ...
(Date:4/29/2016)... ... 29, 2016 , ... Our bodies are bombarded daily by environmental and lifestyle ... these stressors is to adopt a more healthful diet, but too many people think ... certified Holistic Nutritionist and the creator of the Newport Beach Cleanse and 14-Day Eating ...
(Date:4/29/2016)... ... April 29, 2016 , ... Conditions were ideal for Global Lyme Alliance’s (GLA) ... with sunny skies, a light breeze and temperatures in the 60s. Over 400 runners, ... Run and Walk and 1-mile walk were held to increase awareness about Lyme ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Mobility Designed ... put pressure on the armpits, the M+D Crutch evenly distributes body weight from the ... wrists and hands when using the crutches than with other crutches. , Co-founders Max ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... 27, 2016 ... in Zürich gab Strekin AG den Start ... zur Erhaltung des Resthörvermögens von Patienten, denen ... die umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden momentan ... wird während der Operation direkt ins Mittelohr ...
(Date:4/27/2016)... , April 27, 2016   ... 42% Growth in Recurring Consumable Sales  Clinical ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of ... its sales for the first quarter ended March 31, ... the execution of its commercial strategy. First ...
Breaking Medicine Technology: